Cullinan Therapeutics, Inc. (CGEM)
(Delayed Data from NSDQ)
$6.20 USD
-0.14 (-2.21%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $6.22 +0.02 (0.32%) 7:58 PM ET
4-Sell of 5 4
F Value D Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
CGEM 6.20 -0.14(-2.21%)
Will CGEM be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CGEM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CGEM
Wall Street Analysts Predict a 292.51% Upside in Cullinan Therapeutics (CGEM): Here's What You Should Know
CGEM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CGEM
180 Bearish Setup appears for CGEM after 2.21% move
CGEM forms Stochastic Buy Signal on September 18
Is CGEM signaling selling opportunity? New 52 Week Closing Low shows up after crashing 5.72%
Lynx1 Capital Management LP Increases Stake in Passage Bio Inc
New 52 Week Closing Low appears for CGEM after 0.94% move